Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Abstract

The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.

• Authors: Hannah K Knudsen, Amanda J Abraham, J Aaron Johnson, Paul M Roman
• Journal: Journal of substance abuse treatment (J Subst Abuse Treat) Vol. 37 Issue 3 Pg. 307-12 (Oct 2009) ISSN: 1873-6483 [Electronic] United States
• PMID: 19577406 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Narcotic Antagonists
• Buprenorphine

Topics

• Buprenorphine (therapeutic use)
• Clinical Trials as Topic
• Cooperative Behavior
• Data Collection
• Evidence-Based Medicine
• Follow-Up Studies
• Humans
• Narcotic Antagonists (therapeutic use)
• Opioid-Related Disorders (rehabilitation)
• Substance Abuse Treatment Centers (methods, trends)
• United States